240 related articles for article (PubMed ID: 23213196)
1. Characterization of neuroblastic tumors using 18F-FDOPA PET.
Lu MY; Liu YL; Chang HH; Jou ST; Yang YL; Lin KH; Lin DT; Lee YL; Lee H; Wu PY; Luo TY; Shen LH; Huang SF; Liao YF; Hsu WM; Tzen KY;
J Nucl Med; 2013 Jan; 54(1):42-9. PubMed ID: 23213196
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
3. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma.
Liu YL; Lu MY; Chang HH; Lu CC; Lin DT; Jou ST; Yang YL; Lee YL; Huang SF; Jeng YM; Lee H; Miser JS; Lin KH; Liao YF; Hsu WM; Tzen KY
Oncotarget; 2016 Apr; 7(14):18774-86. PubMed ID: 26959748
[TBL] [Abstract][Full Text] [Related]
5. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.
Melzer HI; Coppenrath E; Schmid I; Albert MH; von Schweinitz D; Tudball C; Bartenstein P; Pfluger T
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1648-58. PubMed ID: 21617976
[TBL] [Abstract][Full Text] [Related]
6. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
7. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.
Lugat A; Drui D; Mirallié E; Kraeber-Bodéré F; Ansquer C
Clin Nucl Med; 2019 Sep; 44(9):738-740. PubMed ID: 31306205
[TBL] [Abstract][Full Text] [Related]
10. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
12. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
13. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
15. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
[TBL] [Abstract][Full Text] [Related]
16. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
Piccardo A; Lopci E; Conte M; Garaventa A; Foppiani L; Altrinetti V; Nanni C; Bianchi P; Cistaro A; Sorrentino S; Cabria M; Pession A; Puntoni M; Villavecchia G; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):57-71. PubMed ID: 21932116
[TBL] [Abstract][Full Text] [Related]
18. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
[TBL] [Abstract][Full Text] [Related]
19. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma.
Wartski M; Jehanno N; Michon J; de Labriolle-Vaylet C; Montravers F
Clin Nucl Med; 2015 Dec; 40(12):969-70. PubMed ID: 26544903
[TBL] [Abstract][Full Text] [Related]
20. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]